The antimycoplasmal activities of the pseudomonicacids isolated from Pseudomonas fluorescens NCIB10586 are reported. Structure-activity relationships of a variety of ester, amide and thiol ester derivatives of the nucleus, monic acid A, are described. Enhanced antimycoplasmal activity is reported for a numberof monic acid Aesters and the most potent derivative, /w-nitrobenzyl monate A, is a 100-fold more active against Mycoplasmahyopneumoniaethan pseudomonicacid A.
Materials and Methods
The isolation and characterisation of the pseudomonic acids has already been described1~4) and the preparation of monic acid Aderivatives has been detailed in a series of Beecham patents.7~13) In general terms the esters were prepared by reaction of the appropriate halide and sodium monate in A^N-dimethylformamide at temperatures ranging from ambient to 80°C. The amides and thiol esters ol monic acid A were obtained by activation 01 monic acid A by mixed anhydride (isobutoxyformic) and addition of the appropriate amine or thiol. All derivatives used were substantially pure by various criteria. Purity was assessed by XHNMR, 13C NMRand IR spectroscopic analysis, TLCand HPLC.Either elemental analysis or accurate mass measurement was obtained for the compounds described. Tylosin tartrate was obtained from the Sigma Chemical Company.
Themycoplasmastrains used were either obtained from the National Collection of TypeCultures or from The American Type Culture Collection as indicated by the suffix code. MICvalues for the mycoplasmas were determined by incorporating dilutions of the compounds from 0.01 /^g/ml to 10 g/ml in mycoplasma Friis medium,10 solidified with 0.65 % agarose (Miles Laboratories) and inoculating the surface with about 104 cells per 1 /A spot of the various mycoplasmas, using a Denley 400 multipoint inoculator. When dry, the plates were incubated aerobically in sealed moistened plastic bags at 37°C for 6 days. The MICwas the lowest concentration of drug which inhibited at least 50% of mycoplasmal growth.
Results and Discussion
The pseudomonic acids (1~4) display markedly different activities (Table 1) . Pseudomonic acid A (1) is the most active metabolite against all five strains of mycoplasma. Pseudomonic acid D (4) differs only in the side chain in structure and has activity approaching that of pseudomonic acid A. Conversion of 1 to either an ester (6) or an amide (7) has little effect on activity (Table 2) . Monic acid A (5), the major metabolic product of pseudomonic acid A in man and animals,15) has no antimycoplasmal activity. Monic acids B and C are also inactive.
Substituted alkyl esters of monic acid A (Table 2) were all antimycoplasmally active. Although the activity varied widely it was concluded that compounds with a similar chain length to pseudomonic acid A displayed equal or better activity but polar functions when positioned close to the nucleus produced less active derivatives.
Pseudomonic acid A is highly bound to porcine serum (96%) and the alkyl esters (23~25) were prepared in a successful attempt to reduce this binding, i.e. 23 18%; 24 34%; and 25 70%. In ad- dition the ethyl and butyl esters were 2 to 5-fold moreactive than the parent compound. A considerable improvement in activity was achieved against M. hyopneumoniae, Mycoplasma hyorhinis and Mycoplasmadispar when benzyl esters were studied (Table 3) . Benzyl monate (27) proved to be 2 to 10-fold more active than the narent comnound(Wand subseaiient investigation of substitution of the benzene ring produced compounds up to 100-fold more active than pseudomonic acid A, e.g. the raeta-nitrobenzyl ester (29) M. hyopneumoniae MIC 0.025^g/ml. In general substitution with electron withdrawing groups produced more active compoundsthan electron donating substituents. Substitution in the meta or para positions was preferable to the ortho position. Substitution in the meta position for the cyano and nitro functions produced the most active derivatives but the methanesulfonyl function was better at the para position, perhaps reflecting a steric factor.
Thiol esters of monic acid A (38 and 39) were slightly more active than the corresponding 0-esters analogues (Table 4) but were found to be unstable in vivo and were not of further interest.
Amides of monic acid A (40~44) exhibited relatively poor antimycoplasmal activity. However, structure-activity relationship noted in the ester series were paralleled for the structurally analogous amides and the most active derivative was the raeta-nitrobenzyl amide (42). The tertiary amide (43) for which there is no ester equivalent had poor antimycoplasmal activity.
In summary, of the pseudomonic acids (1~4), the most abundant metabolite, pseudomonic acid A, possesses the most useful activity against mycoplasma. Although the nucleus, monic acid A (5), is inactive, derivatives and particularly benzyl esters show enhanced activities against M. hyopneumoniae, M. hyorhinis> M. dispar and Mycoplasma pneumoniae but not Mycoplasma bovis. The most potent derivative tested was m-nitrobenzyl monate A (29).
